Flexion Phase II data for FX005 gives clinical PoC in arthritis pain
This article was originally published in Scrip
Flexion Therapeutics reported topline data from a Phase II proof-of-concept study that showed that its lead anti-inflammatory drug candidate FX005 was well-tolerated, provided sustained pain relief and improved joint function for patients with moderate osteoarthritis in the knee.
You may also be interested in...
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.